Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients

Clinical trial NCT05669742 · RECRUITING

Trial details

NCT number: NCT05669742
Sponsor: Tanta University
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics

Start date: 2023-05-25
Primary completion: 2026-06-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.